Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
5 High Limit Outer Hard Drives For Information Stockpiling - 2Inside Kathy Hilton’s Christmas pajama party: caviar bumps, champagne vending machines and a mansion full of Housewives
- 3the 6 Shrewd Beds for seniors: A Complete Survey
- 4Nations for Youngsters to Visit
- 5Far-right leader Le Pen to attend Brigitte Bardot's funeral
- Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- Extraordinary Snowboarding Objections All over the Planet
- The most effective method to Beat Dental Tension and Guarantee Customary Exams
- Congress is running out of time to extend ACA subsidies as the GOP moves on to an alternative plan. Here's where things stand.
- Closets for Your Room: Plan and Utility Features
- Over 60 local leaders push Netanyahu to halt haredi draft bill, warn of social rift
- Google's proposed data center in orbit will face issues with space debris in an already crowded orbit
- NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- Qatar, Ireland accuse Israel of using chemical weapons on Palestinians, demand watchdog probe use
